lobbying_activities: 1520821

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1520821	df106649-58e7-48fb-a6a6-f46f8ec2f561	Q1	APOTEX CORP.	310973	APOTEX CORP.	2014	first_quarter	PHA	Federal policy regarding Public Law 113-54, the Drug Quality and Security Act, Title II, Drug Supply Chain Security, Section 581, Definitions, provision relating to the definition of manufacturer;Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE		130000	0	0	2014-04-17T09:36:05.783000-04:00